Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma

Abstract

In a prospective study we examined 38 patients with primary bronchogenic carcinoma to validate the use of indium-111 pentetreotide (IPT) as a diagnostic tool. Of these 38 patients, 25 had small cell lung cancer (SCLC) and 13, non-small cell lung cancer (NSCLC). The aim of the study was to investigate whether (a) the disease can be reliably detected, (b) IPT allows differentiation between SCLC and NSCLC and (c) IPT provides further information on metastatic disease. After giving their informed consent the patients were injected and imaged 4 and 24 h later using a planar whole-body technique. In addition single-photon emission tomography of the thorax and, if necessary, other areas of the body was performed at 24 h. In the 25 patients with SCLC 22 sites of primary tumour were correctly identified (true-positive, TP); one was false-negative (FN) and two were true-negative (TN), the patients being in full remission. Metastases were correctly identified in ten instances (lung, bone and brain), while the findings were FN in five cases. An additional six FN findings resulted in the area of the upper abdomen due to the physiological uptake in the liver, spleen and kidneys. In the 13 patients with NSCLC, ten findings were TP and 3 FN with respect to the primary tumour. Two FNs were squamous cell carcinoma, and one, adenocarcinoma. Metastases were TP in nine cases and FN in one.(ABSTRACT TRUNCATED AT 250 WORDS)

Somatostatin, Its Receptors and Analogs, in Lung Cancer

“…Two further studies have confirmed that [ 111 In]pentetreotide scintigraphy is effective in the localization of NSCLC tumors, detecting the primary tumor in 40 of 40 [86] and 10 of 13 patients, respectively [87]. However, metastatic sites of disease were not as frequently detected, thereby demonstrating the limitations of the technique.…”

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

“…Pituitary tumors (Kwekkeboom et al 1999) GEPNETs Gastrinomas (De Kerviler et al 1994, Gibril et al 1996 Nonfunctioning endocrine pancreatic tumors (Krenning et al 1993, Lebtahi et al 1997 Functioning endocrine pancreatic tumors except insulinomas (Krenning et al 1993, Lebtahi et al 1997 Carcinoids (Kwekkeboom et al 1993a, Westlin et al 1993, Ahlman et al 1994, Kalkner et al 1995 Paragangliomas (Kwekkeboom et al 1993b, Telischi et al 2000, Duet et al 2003) Small cell lung cancer (Kirsch et al 1994, Kwekkeboom et al 1994, Bombardieri et al 1995, Reisinger et al 1998 Meningiomas (Haldemann et al 1995) Sarcoidosis and other granulomatous diseases (Vanhagen et al 1994, Kwekkeboom et al 1998) Graves' disease and Graves' ophthalmopathy (Postema et al 1994, Krassas et al 1995 Intermediate sensitivity Insulinoma (Krenning et al 1993, Zimmer et al 1996 Medullary thyroid carcinoma (Kwekkeboom et al 1993c, Tisell et al 1997, Adams et al 1998 PET with these ligands was reported to be more sensitive than SRI with [ 111 In-DTPA 0 ]octreotide. These PET ligands, however, have to be synthesized in the close vicinity of or in the hospital where the administration to the patient is to take place.…”

Diagnosis and radioguided surgery with 111In-pentetreotide in a patient with paraneoplastic Cushing's syndrome due to a bronchial carcinoid

“…Therefore we postulated the use of radiolabelled OCT to localize the site of the tumour and to discriminate between ASPA and ectopically secreting ACTH tumour. The premise for our attempt was based on recent reports showing in vivo uptake of radiolabelled OCT in a large percentage of bronchial and abdominal carcinoids as well as in SCLC and other neuroendocrine tumours (10,11).…”